# Gemcitabine

## Gemzar inj 200mg

| 藥物代碼 | IGEM |
| :--- | :--- |
| 適應症 | 1-line treatment of metastatic breast cancer \(in combination with paclitaxel\) after failure of adjuvant chemotherapy which contained an anthracycline \(unless contraindicated\). 1-line treatment \(in combination with cisplatin\) of inoperable, locally advanced \(stage IIIA or IIIB\) or metastatic \(stage IV\) non-small cell lung cancer \(NSCLC\). Treatment of advanced ovarian cancer, pancreatic cancer \(locally advanced or metastatic\). |
| 副作用 | Myelosuppression with anemia, leukopenia or thrombocytopenia; nausea & vomiting, diarrhea & stomatitis; transient elevations in serum transminases; mild proteinuria & hematuria, hemolytic uremic syndrome \(discontinue\); fever & flu-like symptoms; rash, pruritus; dyspnea, occasionally accompanied by bronchospasm, pulmonary toxicity \(discontinue\); edema; infections, sepsis \(rare\); alopecia; paresthesia; inj site reactions; allergic reactions; CV events \(rare\).Cardiovascular: Peripheral edema \(20% \)Dermatologic: Alopecia \(15% to 90% \), Rash \(10% to 30% \)Endocrine metabolic: Hyperglycemia \(30% \), Hypomagnesemia \(30% \)Gastrointestinal: Constipation \(10% to 42%\), Diarrhea \(14% to 25% \), Nausea and vomiting \(64% to 96% \), StomatitisHematologic: Anemia, All grade \(65% to 89% \), Leukopenia, All grade \(21% to 86% \), Neutropenia, All grade \(62% to 90% \), Thrombocytopenia, All grade \(24% to 85% \)Hepatic: Alkaline phosphatase raised \(16% to 71% \), ALT/SGPT level raised \(6% to 72% \), AST/SGOT level raised \(3% to 72% \)Immunologic: Infectious disease \(8 to 28% \)Musculoskeletal: Arthralgia \(24% \), Myalgia \(33% \)Neurologic: Paresthesia \(2% to 38% \), Peripheral motor neuropathy \(15% to 35% \), Sensory neuropathy \(23% to 64% \)Otic: Hearing disorder \(25% \)Renal: Hematuria \(13% to 35% \), Proteinuria \(10% to 45% \), Serum creatinine raised \(2% to 38% \)Respiratory: Dyspnea \(1% to 23% \)Other: Fatigue \(40% \), Fever \(6% to 41% \), Pain \(10% to 48% \) |
| 禁忌 | Patients with a known hypersensitivity to gemcitabine. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Breast cancer \(metastatic\): IV: 1,250 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days \(in combination with paclitaxel\). Non-small cell lung cancer \(inoperable, locally advanced, or metastatic\): IV: 1,000 mg/m2 over 30 minutes days 1, 8, and 15; repeat cycle every 28 days \(in combination with cisplatin\) or 1,250 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days \(in combination with cisplatin\). Ovarian cancer \(advanced\): IV: 1,000 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days \(in combination with carboplatin\). Pancreatic cancer \(locally advanced or metastatic\): IV: Initial: 1,000 mg/m2 over 30 minutes once weekly for 7 weeks followed by 1 week rest; then once weekly for 3 weeks out of every 4 weeks. |
| 肝功能異常 | 需 調 整 劑 量  嚴重肝功能損傷者應停藥 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | Micromedex:Infant risk cannot be reled out. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度約 0.1 mg/mL，室溫安定性維持 24 小時。本藥品不可冷藏，藥物會產生結晶。 3. 監測CBC、肝腎功能。 |

